doi:10.3969/j.issn.1004-583X.2023.09.013

Abstract

CLC Number:

R742.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.09.013

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I9/845

Figures/Tables 1

References 64

[1]	Dorsey ER, Sherer T, Okun MS, et al. The emerging evidence of the parkinson pandemic[J]. J Parkinsons Dis, 2018, 8(s1): S3-S8.
[2]	王璐璐, 董露露, 王天俊. 多巴胺转运体99mTc-TRODAT-1 SPECT显像在帕金森病诊断中的研究进展[J]. 临床荟萃, 2022, 37(5): 463-466.
[3]	梁战华, 王琰, 赵航, 等. 帕金森病早期运动症状的临床分析[J]. 临床荟萃, 2011, 26(19): 1706-1708.
[4]	De Pablo-Fernandez E, Goldacre R, Pakpoor J, et al. Association between diabetes and subsequent parkinson disease: A record-linkage cohort study[J]. Neurology, 2018, 91(2): e139-e142.
[5]	Wang Y, Bergström J, Ingelsson M, et al. Studies on alpha-synuclein and islet amyloid polypeptide interaction[J]. Front Mol Biosci, 2023, 10: 1080112. doi: 10.3389/fmolb.2023.1080112 URL
[6]	Sandyk R. The relationship between diabetes mellitus and parkinson's disease[J]. Int J Neurosci, 1993, 69(1-4): 125-130. doi: 10.3109/00207459309003322 pmid: 8082998
[7]	Hu G, Jousilahti P, Bidel S, et al. Type 2 diabetes and the risk of parkinson's disease[J]. Diabetes Care, 2007, 30(4): 842-847. doi: 10.2337/dc06-2011 pmid: 17251276
[8]	Driver JA, Smith A, Buring JE, et al. Prospective cohort study of type 2 diabetes and the risk of parkinson's disease[J]. Diabetes Care, 2008, 31(10): 2003-2005. doi: 10.2337/dc08-0688 pmid: 18599528
[9]	Xu Q, Park Y, Huang X, et al. Diabetes and risk of parkinson's disease[J]. Diabetes Care, 2011, 34(4): 910-915. doi: 10.2337/dc10-1922 pmid: 21378214
[10]	Sun Y, Chang YH, Chen HF, et al. Risk of parkinson disease onset in patients with diabetes: A 9-year population-based cohort study with age and sex stratifications[J]. Diabetes Care, 2012, 35(5): 1047-1049. doi: 10.2337/dc11-1511 pmid: 22432112
[11]	Kotagal V, Albin RL, Müller ML, et al. Clinical features of parkinson disease when onset of diabetes came first: A case-control study[J]. Neurology, 2012, 79(17): 1835-1836. doi: 10.1212/WNL.0b013e3182742edb pmid: 23091078
[12]	Melgoza IP, Jilani R, Shehzad Z, et al. Comment on rhee et al. association between glycemic status and the risk of parkinson disease: A nationwide population-based study.[J]. Diabetes Care, 2021, 44(5): e95-e96.
[13]	Ou R, Wei Q, Hou Y, et al. Effect of diabetes control status on the progression of parkinson's disease: A prospective study[J]. Ann Clin Transl Neurol, 2021, 8(4): 887-897. doi: 10.1002/acn3.v8.4 URL
[14]	Sánchez-Gómez A, Díaz Y, Duarte-Salles T, et al. Prediabetes, type 2 diabetes mellitus and risk of parkinson's disease: A population-based cohort study[J]. Parkinsonism Relat Disord, 2021, 89: 22-27. doi: 10.1016/j.parkreldis.2021.06.002 URL
[15]	Han K, Kim B, Lee SH, et al. A nationwide cohort study on diabetes severity and risk of parkinson disease[J]. NPJ Parkinsons Dis, 2023, 9(1): 11. doi: 10.1038/s41531-023-00462-8 pmid: 36707543
[16]	Rhea EM, Rask-Madsen C, Banks WA. Insulin transport across the blood-brain barrier can occur independently of the insulin receptor[J]. J Physiol, 2018, 596(19): 4753-4765. doi: 10.1113/tjp.2018.596.issue-19 URL
[17]	Pomytkin I, Costa-Nunes JP, Kasatkin V, et al. insulin receptor in the brain: mechanisms of activation and the role in the CNS pathology and treatment[J]. CNS Neurosci Ther, 2018, 24(9): 763-774. doi: 10.1111/cns.12866 pmid: 29691988
[18]	Morris JK, Bomhoff GL, Gorres BK, et al. Insulin resistance impairs nigrostriatal dopamine function[J]. Exp Neurol, 2011, 231(1): 171-180. doi: 10.1016/j.expneurol.2011.06.005 pmid: 21703262
[19]	Wang L, Zhai YQ, Xu LL, et al. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice[J]. Exp Neurol, 2014, 251: 22-29. doi: 10.1016/j.expneurol.2013.11.001 pmid: 24220636
[20]	Chou SY, Chan L, Chung CC, et al. Altered insulin receptor substrate 1 phosphorylation in blood neuron-derived extracellular vesicles from patients with parkinson's disease[J]. Front Cell Dev Biol, 2020, 8: 564641. doi: 10.3389/fcell.2020.564641 URL
[21]	Hogg E, Athreya K, Basile C, et al. High prevalence of undiagnosed insulin resistance in non-diabetic subjects with parkinson's disease[J]. J Parkinsons Dis, 2018, 8(2): 259-265.
[22]	Hipkiss AR. On the Relationship between energy metabolism, proteostasis, aging and parkinson's disease: Possible causative role of methylglyoxal and alleviative potential of carnosine[J]. Aging Dis, 2017, 8(3): 334-345. doi: 10.14336/AD.2016.1030
[23]	刘媛媛, 姚丽芬, 徐春晶, 等. 帕金森病患者血清中sRAGE水平及其临床意义[J]. 神经疾病与精神卫生, 2014, 14(2): 191-193.
[24]	Chung SS, Ho EC, Lam KS, et al. Contribution of polyol pathway to diabetes-induced oxidative stress[J]. J Am Soc Nephrol, 2003, 14(< W>8 Suppl 3): S233-S236.
[25]	Pang L, Lian X, Liu H, et al. Understanding diabetic neuropathy: Focus on oxidative stress[J]. Oxid Med Cell Longev, 2020, 2020: 9524635.
[26]	Alipour M, Salehi I, Ghadiri SF. Effect of exercise on diabetes-induced oxidative stress in the rat hippocampus[J]. Iran Red Crescent Med J, 2012, 14(4): 222-228.
[27]	Franco-Iborra S, Vila M, Perier C. The Parkinson disease mitochondrial hypothesis: Where are we at?[J]. Neuroscientist, 2016, 22(3): 266-277. doi: 10.1177/1073858415574600 pmid: 25761946
[28]	Benilova I, Karran E, De Strooper B. The toxic aβ oligomer and alzheimer's disease: An emperor in need of clothes[J]. Nat Neurosci, 2012, 15(3): 349-357. doi: 10.1038/nn.3028 pmid: 22286176
[29]	Niedzielska E, Smaga I, Gawlik M, et al. Oxidative stress in neurodegenerative diseases[J]. Mol Neurobiol, 2016, 53(6): 4094-4125. doi: 10.1007/s12035-015-9337-5 pmid: 26198567
[30]	Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development[J]. Science, 2011, 333(6048): 1456-1458. doi: 10.1126/science.1202529 pmid: 21778362
[31]	Ronan JL, Wu W, Crabtree GR. From neural development to cognition: Unexpected roles for chromatin[J]. Nat Rev Genet, 2013, 14(5): 347-359. doi: 10.1038/nrg3413 pmid: 23568486
[32]	Bartels AL, Willemsen AT, Doorduin J, et al. [11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in parkinson's disease?[J]. Parkinsonism Relat Disord, 2010, 16(1): 57-59. doi: 10.1016/j.parkreldis.2009.05.005 URL
[33]	Renaud J, Bassareo V, Beaulieu J, et al. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: Preferential degeneration of the nigrostriatal motor pathway[J]. Neurobiol Aging, 2018, 69: 117-128. doi: S0197-4580(18)30166-0 pmid: 29890391
[34]	Satrom KM, Ennis K, Sweis BM, et al. Neonatal hyperglycemia induces CXCL10/CXCR3 signaling and microglial activation and impairs long-term synaptogenesis in the hippocampus and alters behavior in rats[J]. J Neuroinflammation, 2018, 15(1): 82. doi: 10.1186/s12974-018-1121-9
[35]	Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in parkinson's disease: Mechanisms of action[J]. Drug Discov Today, 2016, 21(5): 802-818. doi: 10.1016/j.drudis.2016.01.013 pmid: 26851597
[36]	Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006, 368(9548): 1696-1705. doi: 10.1016/S0140-6736(06)69705-5 pmid: 17098089
[37]	Aarsland D, Påhlhagen S, Ballard CG, et al. Depression in parkinson disease--epidemiology, mechanisms and management[J]. Nat Rev Neurol, 2011, 8(1): 35-47. doi: 10.1038/nrneurol.2011.189 pmid: 22198405
[38]	Li Y, Liu W, Li L, et al. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation[J]. Eur J Pharmacol, 2017, 797: 162-172. doi: S0014-2999(16)30762-2 pmid: 27913104
[39]	Nowell J, Blunt E, Edison P. Incretin and insulin signaling as novel therapeutic targets for alzheimer's and parkinson's disease[J]. Mol Psychiatry, 2023, 28(1): 217-229. doi: 10.1038/s41380-022-01792-4
[40]	Zhang L, Zhang L, Li Y, et al. The novel dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of parkinson's disease[J]. J Parkinsons Dis, 2020, 10(2): 523-542.
[41]	Yuan Z, Li D, Feng P, et al. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of parkinson's disease[J]. Eur J Pharmacol, 2017, 812: 82-90. doi: S0014-2999(17)30436-3 pmid: 28666800
[42]	Trushina E, Trushin S, Hasan MF. Mitochondrial complex I as a therapeutic target for Alzheimer's disease[J]. Acta Pharm Sin B, 2022, 12(2): 483-495. doi: 10.1016/j.apsb.2021.11.003 pmid: 35256930
[43]	Ryu YK, Park HY, Go J, et al. Metformin inhibits the development of L-DOPA-induced dyskinesia in a murine model of parkinson's disease[J]. Mol Neurobiol, 2018, 55(7): 5715-5726. doi: 10.1007/s12035-017-0752-7 URL
[44]	Wahlqvist ML, Lee MS, Hsu CC, et al. Metformin-inclusive sulfonylurea therapy reduces the risk of parkinson's disease occurring with type 2 diabetes in a taiwanese population cohort[J]. Parkinsonism Relat Disord, 2012, 18(6): 753-758. doi: 10.1016/j.parkreldis.2012.03.010 URL
[45]	Shi Q, Liu S, Fonseca VA, et al. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus[J]. BMJ Open, 2019, 9(7): e024954.
[46]	Qiu X, Wang Q, Hou L, et al. Inhibition of NLRP3 inflammasome by glibenclamide attenuated dopaminergic neurodegeneration and motor deficits in paraquat and maneb-induced mouse parkinson's disease model[J]. Toxicol Lett, 2021, 349: 1-11. doi: 10.1016/j.toxlet.2021.05.008 URL
[47]	Lietzau G, Magni G, Kehr J, et al. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging[J]. Neurobiol Aging, 2020, 89: 12-23. doi: S0197-4580(20)30012-9 pmid: 32143981
[48]	Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS[J]. Neuroscience, 2004, 123(1): 131-145. doi: 10.1016/j.neuroscience.2003.08.064 pmid: 14667448
[49]	Carta AR. PPAR-γ: Therapeutic prospects in parkinson's disease[J]. Curr Drug Targets, 2013, 14(7): 743-751. pmid: 23469878
[50]	Zhao H, Zhuo L, Sun Y, et al. Thiazolidinedione use and risk of parkinson's disease in patients with type 2 diabetes mellitus[J]. NPJ Parkinsons Dis, 2022, 8(1): 138. doi: 10.1038/s41531-022-00406-8 pmid: 36271052
[51]	Brauer R, Bhaskaran K, Chaturvedi N, et al. Glitazone treatment and incidence of parkinson's disease among people with diabetes: A retrospective cohort study[J]. PLoS Med, 2015, 12(7): e1001854.
[52]	Chang YH, Yen SJ, Chang YH, et al. Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus[J]. Eur J Neurol, 2021, 28(2): 430-437. doi: 10.1111/ene.v28.2 URL
[53]	Connolly JG, Bykov K, Gagne JJ. Thiazolidinediones and parkinson disease: A cohort study[J]. Am J Epidemiol, 2015, 182(11): 936-944. doi: 10.1093/aje/kwv109 pmid: 26493264
[54]	Rizzo MR, Barbieri M, Boccardi V, et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment[J]. J Gerontol A Biol Sci Med Sci, 2014, 69(9): 1122-1131. doi: 10.1093/gerona/glu032 URL
[55]	ElGamal RZ, Tadros MG, Menze ET. Linagliptin counteracts rotenone's toxicity in non-diabetic rat model of parkinson's disease: Insights into the neuroprotective roles of DJ-1, SIRT-1/Nrf-2 and implications of HIF1-α[J]. Eur J Pharmacol, 2023, 941: 175498. doi: 10.1016/j.ejphar.2023.175498 URL
[56]	Safar MM, Abdelkader NF, Ramadan E, et al. Novel mechanistic insights towards the repositioning of alogliptin in parkinson's disease[J]. Life Sci, 2021, 287: 120132. doi: 10.1016/j.lfs.2021.120132 URL
[57]	Svenningsson P, Wirdefeldt K, Yin L, et al. Reduced incidence of parkinson's disease after dipeptidyl peptidase-4 inhibitors-a nationwide case-control study[J]. Mov Disord, 2016, 31(9): 1422-1423. doi: 10.1002/mds.26734 URL
[58]	Heni M, Hennige AM, Peter A, et al. Insulin promotes glycogen storage and cell proliferation in primary human astrocytes[J]. PLoS One, 2011, 6(6): e21594.
[59]	Born J, Lange T, Kern W, et al. Sniffing neuropeptides: A transnasal approach to the human brain[J]. Nat Neurosci, 2002, 5(6): 514-516. doi: 10.1038/nn849 pmid: 11992114
[60]	Kullmann S, Blum D, Jaghutriz BA, et al. Central insulin modulates dopamine signaling in the human striatum[J]. J Clin Endocrinol Metab, 2021, 106(10): 2949-2961. doi: 10.1210/clinem/dgab410 pmid: 34131733
[61]	Iravanpour F, Dargahi L, Rezaei M, et al. Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of parkinson's disease[J]. CNS Neurosci Ther, 2021, 27(3): 308-319. doi: 10.1111/cns.13609 pmid: 33497031
[62]	Lopez VF, Luque GM, Brie B, et al. Dopaminergic drugs in type 2 diabetes and glucose homeostasis[J]. Pharmacol Res, 2016, 109: 74-80. doi: 10.1016/j.phrs.2015.12.029 pmid: 26748034
[63]	Tavares G, Marques D, Barra C, et al. Dopamine d2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes[J]. Mol Metab, 2021, 51: 101241. doi: 10.1016/j.molmet.2021.101241 URL
[64]	Andersen IB, Andreassen M, Krogh J. the effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials[J]. Diabetes Obes Metab, 2021, 23(1): 58-67. doi: 10.1111/dom.v23.1 URL

出版年份	研究设计	结论
2007	前瞻性队列研究	T2DM与PD发生风险增加有关^[7]
2008	前瞻性队列研究	T2DM病史与PD发生风险增加有关,校正混杂因素和排除已知血管疾病受试者后,仍有相关性^[8]
2011	前瞻性队列研究	T2DM会增加PD发生风险^[9]
2012	回顾性队列研究	校正其他变量后,T2DM会增加PD发病率^[10]
2012	病例对照研究	T2DM是PD症状严重程度的危险因素^[11]
2018	回顾性队列研究	T2DM增加PD发生率^[4]
2020	前瞻性队列研究	T2DM患者PD风险增加,PD发病率与高血糖暴露程度呈正比^[12]
2021	前瞻性队列研究	血糖控制不佳的T2DM是PD患者运动症状加重的独立危险因素^[13]
2021	回顾性队列研究	T2DM前期和T2DM均增加PD发生率^[14]
2023	回顾性队列研究	T2DM严重程度与PD发生风险增加有关^[15]

出版年份	研究设计	结论
2007	前瞻性队列研究	T2DM与PD发生风险增加有关^[7]
2008	前瞻性队列研究	T2DM病史与PD发生风险增加有关,校正混杂因素和排除已知血管疾病受试者后,仍有相关性^[8]
2011	前瞻性队列研究	T2DM会增加PD发生风险^[9]
2012	回顾性队列研究	校正其他变量后,T2DM会增加PD发病率^[10]
2012	病例对照研究	T2DM是PD症状严重程度的危险因素^[11]
2018	回顾性队列研究	T2DM增加PD发生率^[4]
2020	前瞻性队列研究	T2DM患者PD风险增加,PD发病率与高血糖暴露程度呈正比^[12]
2021	前瞻性队列研究	血糖控制不佳的T2DM是PD患者运动症状加重的独立危险因素^[13]
2021	回顾性队列研究	T2DM前期和T2DM均增加PD发生率^[14]
2023	回顾性队列研究	T2DM严重程度与PD发生风险增加有关^[15]

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 64

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Jiuxue, Li Na, Jin Wei, Wang Shuo, Chang Yajun, Wang Tianjun. Correlation between serum uric acid, homocysteine and cystatin C levels with motor symptoms and cognitive function in Parkinson's disease patients [J]. Clinical Focus, 2024, 39(2): 125-129.
[2]	. [J]. Clinical Focus, 2023, 38(9): 855-858.
[3]	. [J]. Clinical Focus, 2023, 38(2): 189-192.
[4]	Li Wenjun, Zhang Ce, Liu Junyan. Improving circulation aggravates the orthostatic hypotension in a patient with Parkinson's disease: A case report [J]. Clinical Focus, 2022, 37(10): 934-937.
[5]	. [J]. Clinical Focus, 2022, 37(5): 463-466.
[6]	Guo Chang, Shen Huinan, Sun Yimeng, Wang Dongyu. Correlation between blood lipid and homocysteine and cognitive impairment in Parkinson's disease [J]. Clinical Focus, 2022, 37(2): 128-132.
[7]	Zhao Hang;Ge Hanming;Liang Zhanhua;Wang Yan. Correlation analysis of individualized treatment compliance and disease progression in patients with Parkinson disease [J]. Clinical Focus, 2015, 30(5): 499-502.
[8]	SUN Lin-juan;XU Sheng-li;ZHOU Ming;MAO Li-jun;CHEN Biao. Protection of cysteamine on 1-methy1-4-phenylpyridinium induced SH-SY5Y in Parkinson's disease cell model by antioxidant [J]. Clinical Focus, 2014, 29(7): 740-743.
[9]	SUN Lin-juan;MAO Li-jun;XU Sheng-li;ZHOU Ming;CHEN Biao. Protection of cysteamine on dopaminergic neurons in Parkinson disease mice model by antioxidant [J]. Clinical Focus, 2013, 28(2): 181-0.
[10]	. [J]. Clinical Focus, 2012, 27(15): 1359-0.
[11]	ZENG Wen-jing;ZHANG Xiao-ying;LI Yan-yun;LIU Yan;LI Yan. Relationship between polymorphism of monoamine oxidase B gene and Parkinson disease in Xinjiang Uygurs [J]. Clinical Focus, 2012, 27(9): 764-766.
[12]	. [J]. CLINICAL FOCUS, 2011, 26(10): 888901-0.
[13]	. [J]. CLINICAL FOCUS, 2011, 26(5): 400-0.
[14]	. [J]. CLINICAL FOCUS, 2010, 25(21): 1931-0.
[15]	ZHANG Li;KONG Yan;XU Zhuan;CHEN Jian-hua;ZHANG Zheng-chun. Diagnostic value on pronton magnetic resonance spectroscopy of lentiform nucleus in Parkinson disease [J]. CLINICAL FOCUS, 2009, 24(13): 1115-1117.